ASX:PCK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PainChek Ltd. provides pain assessment solutions primarily in Australia and Europe.


Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has PainChek's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PCK's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-10.7%

PCK

-0.7%

AU Healthcare Services

-1.5%

AU Market


1 Year Return

-26.5%

PCK

-21.5%

AU Healthcare Services

-12.2%

AU Market

Return vs Industry: PCK underperformed the Australian Healthcare Services industry which returned -21.5% over the past year.

Return vs Market: PCK underperformed the Australian Market which returned -12.2% over the past year.


Shareholder returns

PCKIndustryMarket
7 Day-10.7%-0.7%-1.5%
30 Day4.2%-8.1%-1.4%
90 Day-16.7%-1.2%13.2%
1 Year-26.5%-26.5%-21.2%-21.5%-8.7%-12.2%
3 Yearn/a106.2%99.4%16.8%1.4%
5 Yearn/a187.6%164.2%34.2%5.2%

Price Volatility Vs. Market

How volatile is PainChek's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PainChek undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PCK (A$0.13) is trading below our estimate of fair value (A$0.41)

Significantly Below Fair Value: PCK is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PCK is unprofitable, so we can't compare its PE Ratio to the XX Healthcare Services industry average.

PE vs Market: PCK is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PCK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PCK is overvalued based on its PB Ratio (21.1x) compared to the AU Healthcare Services industry average (4.7x).


Next Steps

Future Growth

How is PainChek forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

100.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: PCK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PCK's is expected to become profitable in the next 3 years.

Revenue vs Market: PCK's revenue (100.3% per year) is forecast to grow faster than the Australian market (4.1% per year).

High Growth Revenue: PCK's revenue (100.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PCK's Return on Equity is forecast to be low in 3 years time (16.6%).


Next Steps

Past Performance

How has PainChek performed over the past 5 years?

-23.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PCK is currently unprofitable.

Growing Profit Margin: PCK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PCK is unprofitable, and losses have increased over the past 5 years at a rate of 23% per year.

Accelerating Growth: Unable to compare PCK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PCK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-1.5%).


Return on Equity

High ROE: PCK has a negative Return on Equity (-193.76%), as it is currently unprofitable.


Next Steps

Financial Health

How is PainChek's financial position?


Financial Position Analysis

Short Term Liabilities: PCK's short term assets (A$6.9M) exceed its short term liabilities (A$822.6K).

Long Term Liabilities: PCK has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: PCK is debt free.

Reducing Debt: PCK has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PCK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PCK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is PainChek current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PCK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PCK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PCK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PCK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PCK's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Philip Daffas

3.92yrs

Tenure

AU$377,500

Compensation

Mr. Philip Daffas, BSc, Dip EENG, MBA, GAICD, has been Managing Director and Director at PainChek Ltd. since September 30, 2016 and serves as its Chief Executive Officer. Mr. Daffas served as Vice Presiden ...


CEO Compensation Analysis

Compensation vs Market: Philip's total compensation ($USD270.51K) is about average for companies of similar size in the Australian market ($USD268.72K).

Compensation vs Earnings: Philip's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Philip Daffas
MD. CEO & Director3.92yrsAU$377.50k1.98%
A$ 2.5m
Ian Hobson
CFO & Company Secretary3.92yrsAU$122.83kno data
Scott Robertson
Chief Technology Officer3.33yrsno datano data
Jeff Hughes
Chief Scientific Officerno datano datano data
David Allsopp
Head of Business Development ANZno datano datano data
Pete Shergill
Head of Business Development UK0.92yrno datano data

3.6yrs

Average Tenure

Experienced Management: PCK's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Philip Daffas
MD. CEO & Director3.92yrsAU$377.50k1.98%
A$ 2.5m
John Murray
Non-Executive Chairman3.92yrsAU$80.00k1.21%
A$ 1.5m
Adam Davey
Non-Executive Director5.92yrsAU$40.00k0.94%
A$ 1.2m
Ross Harricks
Non-Executive Director3.92yrsAU$40.00k0.60%
A$ 749.2k
Jennifer Abbey
Member of Clinical Advisory Board2.17yrsno datano data

3.9yrs

Average Tenure

75yo

Average Age

Experienced Board: PCK's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.3%.


Top Shareholders

Company Information

PainChek Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PainChek Ltd.
  • Ticker: PCK
  • Exchange: ASX
  • Founded:
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$124.307m
  • Shares outstanding: 1.04b
  • Website: https://www.painchek.com

Location

  • PainChek Ltd.
  • 35 Lime Street
  • Suite 401
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PCKASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 2018
PCKCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJan 2018

Biography

PainChek Ltd. provides pain assessment solutions primarily in Australia and Europe. The company offers PainChek, a smartphone and tablets pain assessment and monitoring device that automatically detects pa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/03 10:44
End of Day Share Price2020/08/03 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.